Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Pearce, IanBanerjee, Sanjiv
Burton, Ben J L
Chakravarthy, Usha
Downey, Louise
Gale, Richard P
Gibson, Jonathan
Patel, Jignesh
Sivaprasad, Sobha
Andrews, Chris
Brittain, Christopher
Warburton, James
Pagliarini, Sergio
Publication date
2015-07-03Subject
Ophthalmology
Metadata
Show full item recordAbstract
To evaluate ranibizumab 0.5 mg using bimonthly monitoring and individualized re-treatment after monthly follow-up for 6 months in patients with visual impairment due to diabetic macular edema (DME).Citation
Ophthalmology . 2015 Sep;122(9):1811-9Type
ArticlePMID
26150052Journal
OphthalmologyPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.ophtha.2015.05.038